Michael Hayden

Michael Hayden

Founder presso 89BIO, INC.

Patrimonio netto: 11 M $ in data 31/03/2024

72 anni
Health Technology
Commercial Services
Consumer Services

Profilo

Michael R.
Hayden
is the founder of Aspreva Pharmaceuticals Corp.
(founded in 2002) and Centre for Molecular Medicine & Therapeutic (founded in 1992).
He is also the founder of NeuroVir Therapeutic, Inc., Prilenia Therapeutics Development Ltd., and 89bio, Inc. (founded in 2018).
Currently, Dr. Hayden holds positions as an Independent Director at Ionis Pharmaceuticals, Inc. (since 2018), a Non-Executive Director at Oxford Biomedica Plc (since 2021), and a Director-Translational Laboratory at the National University of Singapore.
He is also a Scientific Director at the Canadian Genetics Diseases Network (since 1990), a Director at the Royal Society of Canada (since 1995), a Lead Director at AbCellera Biologics, Inc. (since 2019), a Director & Program Director at the Translational Laboratory in Genetic Medicine, a Venture Advisor at Andera Partners SCA (since 2018), a Professor at the University of British Columbia (since 1983), a Venture Partner at Forbion Capital Partners Management Holding BV (since 2022), and a Member of the American Society of Clinical Investigation (since 1992).
In his former positions, Dr. Hayden served as a Director at Lycera Corp., Many Bright Ideas Technologies, Inc., and the Agency for Science, Technology & Research.
He was also a Director at the Michael Smith Foundation for Health Research (2011-2012), an Independent Director at Aurinia Pharmaceuticals, Inc. (2018-2021), the Chief Scientific Officer at Teva Pharmaceutical Industries Ltd.
(2013-2017), and the President & Chief Scientific Officer at GlobaR&D Co., Ltd.
Dr. Hayden obtained his undergraduate and doctorate degrees from the University of Cape Town in 1975 and 1979, respectively.
Dr. Hayden is also the founder of NeuroVir Therapeutic, Inc., Prilenia Therapeutics Development Ltd...

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValorizzazioneData di valutazione
22/09/2023 1 441 642 ( 0.49% ) 7 M $ 31/03/2024
01/02/2024 246 430 ( 0.26% ) 3 M $ 31/03/2024
17/07/2023 32 219 ( 0.02% ) 1 M $ 31/03/2024
13/11/2023 39 973 ( 0.04% ) 101 497 $ 31/03/2024

Posizioni attive di Michael Hayden

SocietàPosizioneInizio
IONIS PHARMACEUTICALS, INC. Director/Board Member 24/09/2018
89BIO, INC. Founder 01/04/2018
ABCELLERA BIOLOGICS INC. Director/Board Member 01/10/2019
OXFORD BIOMEDICA PLC Director/Board Member 15/07/2021
Consultant / Advisor 01/01/2018
Private Equity Investor 31/03/2022
Founder 01/10/2018
National University of Singapore Corporate Officer/Principal -
American Society of Clinical Investigation Corporate Officer/Principal 01/01/1992
░░░░░░░░░░░░░ ░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
Tutte le posizioni attive di Michael Hayden

Precedenti posizioni note di Michael Hayden

SocietàPosizioneFine
░░░░░ ░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░ ░░░░░ ░░░░░░░░░░ ░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░ ░░░░░ ░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di Michael Hayden

Formazione di Michael Hayden

University of Cape Town Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Michael Hayden

Relazioni

100 +

Relazioni di 1° grado

27

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa8
TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Health Technology

IONIS PHARMACEUTICALS, INC.

Health Technology

OXFORD BIOMEDICA PLC

Health Technology

XENON PHARMACEUTICALS INC.

Health Technology

MANY BRIGHT IDEAS TECHNOLOGIES INC.

Health Services

AURINIA PHARMACEUTICALS INC.

Health Technology

ABCELLERA BIOLOGICS INC.

Health Technology

89BIO, INC.

Health Technology

Aziende private16

Health Technology

Health Technology

Finance

Commercial Services

Finance

Miscellaneous

Commercial Services

American Society of Clinical Investigation

Commercial Services

Commercial Services

Centre for Molecular Medicine & Therapeutic

Health Technology

Translational Laboratory in Genetic Medicine

Commercial Services

Health Technology

GlobaR&D Co. ,Ltd

Vedi le connessioni aziendali
  1. Borsa valori
  2. Insiders
  3. Michael Hayden